Eli Lilly raises UK price of obesity drug
Digest more
Eli Lilly's obesity drugs delivered 38% revenue growth in the second quarter; but its oral GLP-1 candidate fell short, achieving only 12.4% weight loss. Viking Therapeutics' dual-formulation obesity program could capture the most profitable patient segment starting in 2027.
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees (nearly $160) for its starting dose of 2.5 mg in India, stepping up competition with Novo Nordisk .
The price of ‘King Kong’ fat jab Mounjaro will almost triple from September adding a potential £2,704 a year to the cost of the drug. Manufacturer Lilly has announced plans to hike the amount it charges private providers in the UK to bring it into ...
Texas Attorney General Ken Paxton has filed a lawsuit against Eli Lilly and Co. (NYSE:LLY), accusing the pharmaceutical giant of bribing medical providers to promote its most profitable drugs, including the widely used GLP-1 medications Mounjaro and Zepbound for diabetes and weight loss.
3d
Straight Arrow News on MSNEli Lilly accused of bribing doctors to prescribe Mounjaro and other drugs
Texas Attorney General Ken Paxton filed a lawsuit against Eli Lilly, accusing the drug maker of bribing doctors to prescribe their medications. Paxton said the quid pro quo arrangements tainted millions of dollars of claims to Texas Medicaid.
Eli Lilly and Company (NYSE:LLY) is among the 11 Best GLP-1 and Weight Loss Stocks to Invest in. Eli Lilly and Company (NYSE:LLY) revealed the topline results of the SURPASS-CVOT Phase 3 trial, which showed that Mounjaro (tirzepatide) was non-inferior to Trulicity (dulaglutide) in reducing significant cardiovascular events (MACE-3) among more than 13,
The Government and pharmaceutical giant Eli Lilly, the creator of weight loss drug Mounjaro, are teaming up to explore and trial innovative solutions to the UK's obesity crisis, inviting NHS organisations to put forward fresh proposals.
Eli Lilly’s GIP/GLP-1 dual receptor agonist Mounjaro (tirzepatide) has demonstrated cardiovascular protection in a late-stage study of patients with type 2 diabetes (T2D) and established atherosclerotic cardiovascular disease.